Pablo Andres Bermudez Hernandez

Pablo Andres Bermudez Hernandez

Auto-generated profile, based on publicly available information

Pablo Andres Bermudez Hernandez

Centro de Investigaciones Fundación Cardioinfantil‐Instituto de Cardiología Bogotá Colombia

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 June 2019 in Cost Effectiveness and Resource Allocation
Verified
Journal Article
Open access
PDF file
DTDario Londoño Trujillo
Dario Londoño Trujillo
NSNESTOR SANDOVAL
NESTOR SANDOVAL
ARAlejandra Taborda Restrepo
Alejandra Taborda Restrepo
CVCindy Lorena Chamorro Velasquez
Cindy Lorena Chamorro Velasquez
MTMaria Teresa Dominguez Torres
Maria Teresa Dominguez Torres
RDRodolfo Jose Dennis
Rodolfo Jose Dennis
In many countries, economic assessments of the routine use of pulse oximetry in the detection of Critical Congenital Heart Disease (CCHD) at birth has not yet been carried out. CCHDs necessarily require medical intervention within the first months of life. This assessment is a priority in low and medium resource countries. The purpose of this study was to assess the cost-effectiveness (CE) relation of pulse oximetry in the detection of cases of CCHD in Colombia. A full economic assessment of the cost-effectiveness type was conducted from the perspective of society. A decision tree was constructed to establish a comparison between newborn physical examination plus pulse oximetry, versus physical examination alone, in the diagnosis of CCHDs. The sensitivity and specificity of pulse oximetry were estimated from a systematic review of the literature; to assess resource use, micro-costing analyses and surveys were conducted. The time horizon of the economic evaluation was the first week after birth and until the first year of life. The incremental cost-effectiveness ratio (ICER) was determined and, to control for uncertainty, deterministic and probabilistic sensitivity analysis were made, including the adoption of different scenarios of budgetary impact. All costs are expressed in US dollars from 2017, using the average exchange rate for 2017 [$2,951.15 COP for 1 dollar]. The costs of pulse oximetry screening plus physical examination were $102; $7 higher than physical examination alone. The effectiveness of pulse oximetry plus the physical examination was 0.93; that is, 0.07 more than the physical examination on its own. The ICER was $100 for pulse oximetry screening; that is, if one wishes to increase 1% the probability of a correct CCHD diagnosis, this amount would have to be invested. A willingness to pay of $26.292 USD (direct medical cost) per probability of a correct CCHD diagnosis was assumed. At current rates and from the perspective of society, newborn pulse oximetry screening at 24 h in addition to physical examination, and considering a time horizon of 1 week, is a cost-effective strategy in the early diagnosis of CCHDs in Colombia. Trial registration “retrospectively registered”.

1 May 2017 in Revista de Salud Pública
Verified
Journal Article
Open access
LPLilia Del Riesgo Prendes
Lilia Del Riesgo Prendes
AMAlba Lucía Salamanca Matta
Alba Lucía Salamanca Matta
PGPedro Agustín Monterrey Gutiérrez
Pedro Agustín Monterrey Gutiérrez
PHPablo Andrés Bermúdez Hernández
Pablo Andrés Bermúdez Hernández
JLJuan Luis Vélez Leal
Juan Luis Vélez Leal
GRGermán Suárez Rodríguez
Germán Suárez Rodríguez
Objetivo Identificar los factores de riesgo maternos, fetales y neonatales asociados a la hipoxia perinatal en los recién nacidos del Hospital Universitario Mayor Mederi (HUM Mederi), período 2007 a 2011.Metodología Del total de recién nacidos (8 837) en los años 2007 a 2011, en el HUMMederi, se tomaron los casos que presentaron asfixia perinatal (AP) según la ACOG u otro diagnóstico de Dificultad Respiratoria (DR). Fuente: Registros del sistema informáticode Servicio de Neonatología del Hospital Universitario Mayor Mederi. Se analizaron los factores de riesgo materno, fetal y neonatal. Los datos se mostraron de acuerdo al número de recién nacidos en cada grupo y en forma porcentual.Resultados La tasa de mortalidad global fue de 10,7. Los valores más bajos fueron enlos años 2010 y 2011: 3.3 y 1.8 espectivamente. Diabetes gestacional, hipertensión, corioamnionitis y placenta previa fueron más frecuentes en el grupo con DR, mientras que hipoglicemia y sepsis lo fueron en el grupo con AP así como hipotonía e hipoactividad entre las alteraciones neurológicas. Fue baja la correspondencia entre las alteraciones neurológicas y el Test de Apgar en los casos diagnosticados con AP.Conclusiones La tasa de mortalidad fue muy baja comparada a nivel regional y local. Hubo mayor número de recién nacidos con asfixia perinatal moderada. Los resultados del estudio coinciden con lo reportado. El mayor número de pre-término en los reciénnacidos con DR enfatiza la importancia de controlar el implemento de acciones para disminuir los factores de riesgo asociados a esta condición.

19 May 2025 in Tropical Medicine & International Health
Verified
Journal Article
Open access
JVJuan Carlos Villar
Juan Carlos Villar
MSMaría Fernanda Saavedra
María Fernanda Saavedra
PBPablo Andrés Bermúdez
Pablo Andrés Bermúdez
EHEliana Váquiro Herrera
Eliana Váquiro Herrera
SVSkarlet Marcell Vásquez
Skarlet Marcell Vásquez
MOMario Javier Olivera
Mario Javier Olivera
Objectives: To determine, in a randomised placebo‐controlled trial, if cutaneous adverse reactions during treatment (CARDT) with Benznidazole occur as often as with Nifurtimox, and whether the dose and duration of treatment change that frequency.Methods: We conducted the EQUITY trial (NCT02369978), allocating Trypanosoma cruzi seropositive adults with no apparent clinical disease to a 120‐day, blinded treatment with Benznidazole, Nifurtimox, or Placebo (ratio 2:2:1). Active treatment groups included either 60‐day conventional‐dose (60CD) regimens (Benznidazole 300 mg/day or Nifurtimox 480 mg/day, followed or preceded by, 60 days of placebo) or 120‐day half‐dose (120HD) regimens (Benznidazole 150 mg/day or Nifurtimox 240 mg/day). CARDT had blinded adjudication as moderate to severe during the follow‐up visits.Results: Among 307 participants, 42 CARDT (17.1%, 95% confidence interval [CI] 12.6–22.4) occurred in 246 receiving active treatment, compared to two CARDT (3.3%, 95% CI 0.0–11.3) in 61 participants receiving placebo. In 122 patients treated with Benznidazole, there were 31 CARDT (25.4%, including eight severe), compared to 11 CARDT (8.9%, including four severe) in 124 individuals treated with Nifurtimox (p < 0.001). Among the 125 participants assigned to the 120HD regimen, there were 26 CARDT (20.8%, including six severe), compared to 16 CARDT (13.2%, including six severe) among 121 in the 60CD group (p = 0.005). The agent‐regime interaction was not significant (p = 0.443). Eleven participants (25%) with CARDT did not complete their treatment.Conclusion: CARDT occurred more frequently with Benznidazole treatment, particularly with longer exposure despite the half‐dose regimen. Clinicians should consider these differences when discussing treatment options with patients receiving nitro derivative agents.

18 March 2025 in BMC Medical Education
Verified
Journal Article
Open access
PDF file
AIAndres Isaza-Restrepo
Andres Isaza-Restrepo
NBNatalia Buitrago-Ricaurte
Natalia Buitrago-Ricaurte
BPBermúdez-Hernández Pablo
Bermúdez-Hernández Pablo
DADaniel Felipe Ariza-Salamanca
Daniel Felipe Ariza-Salamanca
IMIbañez-Pinilla Milciades
Ibañez-Pinilla Milciades
VJVergel John
Vergel John
Background: Using Virtual Patients (VPs) in medical education has gained popularity, especially during the SARS-CoV-2 pandemic, which restricted traditional clinical training. VPs provide a learning platform for students to refine their clinical reasoning and decision-making skills in a risk-free environment. Although the educational benefits of VPs are well known, there is still a need for validated tools to assess student perceptions, which are key to optimizing learning outcomes. The Virtual Patient Integration Rating Scale (VPIRS) has made a valuable contribution in this regard, having been established in English-speaking contexts, but its applicability in Ibero-American countries remains poorly explored. This study aimed to fill this gap by transculturally validating VPIRS for Spanish-speaking medical education environments, ensuring it reflects cultural nuances. Methods: We conducted a two-phase transcultural validation of the VPIRS on medical students at the Universidad del Rosario. First, we translated and culturally adapted the VPIRS, using the modified Delphi method for face validation. Second, we assessed the construct validity, internal consistency, reproducibility, and reliability of the scale through a test-retest approach with 153 participants, using descriptive statistics, factor analysis, and reliability testing in SPSS. Results: The VPIRS was successfully adapted and validated for transcultural use in Spanish (VPIRS-E). The exploratory and factor analyses maintained the original scale’s four-dimensional structure, explaining 61.8% of the total variance, with an overall Cronbach’s alpha of 0.826. Test-retest reliability demonstrated robust intraclass correlation coefficients ranging from 0.8 to 0.9. Conclusion: The VPIRS-E is a reliable and valid instrument that has maintained the structural integrity of the original scale and has demonstrated strong internal consistency across all of its domains. These results demonstrate the suitability of the VPIRS-E to assess medical students’ perceptions of the use of VPs in Spanish-speaking learning contexts. The successful validation of this instrument also opens avenues for expanded international comparative studies, allowing fora deeper understanding of the effective integration of VPs in different medical education curricula.